Viatris
VIATRIS INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$14.3B
Operating marginCalculated
-18.6%
Net assets to total assetsCalculated
Could not be retrieved
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-18.6%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-5.4%
Capital efficiency
Could not be retrieved
Revenue and profit
Performance, financial position and capital allocation
Viatris
Recent performance trends
Viatris
Cash flow trends
Consolidated indicators (7 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$17.9 billion | US$16.3 billion | US$15.4 billion | US$14.7 billion | US$14.3 billion |
| Operating income | US$-34.00 million | US$1.6 billion | US$0.8 billion | US$10.10 million | US$-2.7 billion |
| Total assets | US$54.8 billion | US$50.0 billion | US$47.7 billion | US$41.5 billion | US$37.2 billion |
| Net cash provided by (used in) operating activities | US$3.0 billion | US$3.0 billion | US$2.9 billion | US$2.3 billion | US$2.3 billion |
| Net cash provided by (used in) investing activities | US$-0.1 billion | US$1.5 billion | US$-0.9 billion | US$1.8 billion | US$-0.4 billion |
| Net cash provided by (used in) financing activities | US$-3.0 billion | US$-3.9 billion | US$-2.3 billion | US$-4.3 billion | US$-1.3 billion |
| Cash and cash equivalents | US$0.7 billion | US$1.3 billion | US$1.0 billion | US$0.7 billion | US$1.3 billion |
Revenue scale in the same industry
Viatris
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 14 companies
- 18 THE Estee Lauder CompaniesFY Jun 2026 US$15.0B
- 19 Regeneron PharmaceuticalsFY Dec 2025 US$14.3B
- 20 ViatrisThis companyFY Dec 2025 US$14.3B
- 21 MosaicFY Dec 2025 US$12.1B
- 22 AIR Products AND ChemicalsFY Sep 2025 US$12.0B
- … 34 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.3 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$2.8 billion | Consolidated | Disclosed |
| Number of employees | 30,000 | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$14.7 billion | Consolidated | Disclosed |
| Net sales | US$14.3 billion | Consolidated | Disclosed |
| Operating income | US$-2.7 billion | Consolidated | Disclosed |
| Total assets | US$37.2 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.5 billion | Consolidated | Disclosed |
| Operating margin | -18.6% | Consolidated | Calculated |
| Net assets to total assets | Cannot be calculated | Not applicable | Not calculated (no stockholders' equity in this year's 10-K) |
| Net margin | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |
| Return on equity | Cannot be calculated | Not applicable | Not calculated (no net income in this year's 10-K) |